Inventor · disambiguated record
Paul Smith
Also filed as: SMITH PAUL · SMITH PAUL ALFRED
12 granted patents·10 pending applications·21 citations·filing 2013–2025
86Inventor score
Top patents by PatentIndex Score
22 records- 0195US11304949B2Treatment of hidradenitis suppurativa using JAK inhibitorsINCYTE CORP·Filed 2019·Granted Apr 19, 2022·8 cites·17 claims
- 0290US12005067B2JAK inhibitor with a vitamin D analog for treatment of skin diseasesINCYTE CORP·Filed 2021·Granted Jun 11, 2024·3 cites·21 claims
- 0388US11957661B2JAK1 pathway inhibitors for the treatment of vitiligoINCYTE CORP·Filed 2021·Granted Apr 16, 2024·2 cites·13 claims
- 0483US11596632B2JAK1 pathway inhibitors for the treatment of gastrointestinal diseaseINCYTE CORP·Filed 2019·Granted Mar 7, 2023·1 cites·18 claims
- 0582US2025099472A1Ruxolitinib for the treatment of prurigo nodularisINCYTE CORP·Filed 2024·Application pending·0 cites
- 0682US2025032498A1Ruxolitinib for the treatment of prurigo nodularisINCYTE CORP·Filed 2024·Application pending·0 cites
- 0780US10208349B2Lipocalin 2 as a biomarker for IL-17 inhibitor therapy efficacyUCB BIOPHARMA SPRL·Filed 2013·Granted Feb 19, 2019·5 cites·6 claims
- 0879US12280054B2Treatment of hidradenitis suppurativa using JAK inhibitorsINCYTE CORP·Filed 2022·Granted Apr 22, 2025·0 cites·10 claims
- 0979US2024075040A1Ruxolitinib for the treatment of prurigo nodularisINCYTE CORP·Filed 2023·Application pending·0 cites
- 1073US12150943B2JAK1 pathway inhibitors for the treatment of gastrointestinal diseaseINCYTE CORP·Filed 2023·Granted Nov 26, 2024·0 cites·7 claims
- 1172US11918581B2Combination therapy comprising JAK pathway inhibitor and rock inhibitorINCYTE CORP·Filed 2022·Granted Mar 5, 2024·0 cites·22 claims
- 1271US2024024328A1Ruxolitinib for the treatment of prurigo nodularisINCYTE CORP·Filed 2023·Application pending·0 cites
- 1370US10537566B2Combinations comprising siponimod and laquinimod for the treatment of multiple sclerosisSMITH PAUL ALFRED·Filed 2015·Granted Jan 21, 2020·2 cites·6 claims
- 1470US2024390378A1Use of jak1 inhibitors for the treatment of cutaneous lupus erythematosus and lichen planus (lp)INCYTE CORP·Filed 2024·Application pending·0 cites
- 1570US2025049817A1Jak inhibitor with a vitamin d analog for treatment of skin diseasesINCYTE CORP·Filed 2024·Application pending·0 cites
- 1669US12268667B2JAK1 pathway inhibitors for the treatment of prurigo nodularisINCYTE CORP·Filed 2022·Granted Apr 8, 2025·0 cites·20 claims
- 1769US2024358680A1Jak1 pathway inhibitors for the treatment of vitiligoINCYTE CORP·Filed 2024·Application pending·0 cites
- 1866US2022347179A1Ruxolitinib for the treatment of prurigo nodularisINCYTE CORP·Filed 2022·Application pending·0 cites
- 1965US11992490B2Use of JAK1 inhibitors for the treatment of cutaneous lupus erythematosus and Lichen planus (LP)INCYTE CORP·Filed 2020·Granted May 28, 2024·0 cites·16 claims
- 2062US11466324B2Lipocalin 2 as a biomarker for IL-17 inhibitor therapy efficacyUCB BIOPHARMA SPRL·Filed 2019·Granted Oct 11, 2022·0 cites·5 claims
- 2161US2023190755A1Topical formulations of PI3K-delta inhibitorsINCYTE CORP·Filed 2022·Application pending·0 cites
- 2258US2025195476A1Jak1 pathway inhibitors for the treatment of prurigo nodularisINCYTE CORP·Filed 2025·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Paul Smith files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →